A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma

NCT06556199 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/Refractory Primary Central Nervous System Lymphoma

Interventions

DRUG: Selinexor
DRUG: Temozolomide
DRUG: Anti-PD-1 monoclonal antibody

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University